Literature DB >> 12672262

Neuroreceptor mechanisms of aggression and its treatment.

Alan C Swann1.   

Abstract

Aggression results from the interaction of multiple systems. It can be classified as predatory, impulsive, or based on a medical condition. The likelihood of aggression is increased by environmental overstimulation or stress, transmitter balances favoring dopamine and excitatory amino acid transmission over serotonin and gamma-aminobutyric acid transmission, and the presence of problems related to impulsivity. Treatments for aggression are based on the underlying causes and generally should combine pharmacologic and environmental or psychotherapeutic measures. Useful pharmacologic agents include mood stabilizers and atypical antipsychotics that combine dopaminergic and serotonergic actions. Drugs acting on nicotine receptors may deserve further attention. Nonpharmacologic measures include behavioral techniques aimed at reducing impulsivity, relapse prevention techniques for substance abuse, and anger management techniques.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12672262

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  25 in total

Review 1.  Antiepileptic drugs for the treatment of post-traumatic stress disorder.

Authors:  Heather A Berlin
Journal:  Curr Psychiatry Rep       Date:  2007-08       Impact factor: 5.285

2.  Stress-related increases in risk taking and attentional failures predict earlier relapse to smoking in young adults: A pilot investigation.

Authors:  Ty S Schepis; Brian E Tapscott; Suchitra Krishnan-Sarin
Journal:  Exp Clin Psychopharmacol       Date:  2016-02-22       Impact factor: 3.157

Review 3.  Mood and anxiety regulation by nicotinic acetylcholine receptors: A potential pathway to modulate aggression and related behavioral states.

Authors:  Marina R Picciotto; Alan S Lewis; Gerrit I van Schalkwyk; Yann S Mineur
Journal:  Neuropharmacology       Date:  2015-01-09       Impact factor: 5.250

4.  Personality and the acute subjective effects of d-amphetamine in humans.

Authors:  Matthew G Kirkpatrick; Chris-Ellyn Johanson; Harriet de Wit
Journal:  J Psychopharmacol       Date:  2013-01-23       Impact factor: 4.153

5.  Interactions between serotonin transporter gene haplotypes and quality of mothers' parenting predict the development of children's noncompliance.

Authors:  Michael J Sulik; Nancy Eisenberg; Kathryn Lemery-Chalfant; Tracy L Spinrad; Kassondra M Silva; Natalie D Eggum; Jennifer A Betkowski; Anne Kupfer; Cynthia L Smith; Bridget Gaertner; Daryn A Stover; Brian C Verrelli
Journal:  Dev Psychol       Date:  2011-11-07

6.  Short- and long-term efficacy and safety of risperidone in adults with disruptive behavior disorders.

Authors:  Carllo Gagiano; Stephen Read; Lilian Thorpe; Mariëlle Eerdekens; Ilse Van Hove
Journal:  Psychopharmacology (Berl)       Date:  2005-01-25       Impact factor: 4.530

7.  Metabolic and reproductive consequences of the serotonin transporter promoter polymorphism (5-HTTLPR) in adult female rhesus monkeys (Macaca mulatta).

Authors:  J B Hoffman; J R Kaplan; B Kinkead; S L Berga; M E Wilson
Journal:  Endocrine       Date:  2007-04       Impact factor: 3.633

Review 8.  Neurobiology of aggression and violence.

Authors:  Larry J Siever
Journal:  Am J Psychiatry       Date:  2008-03-17       Impact factor: 18.112

9.  Aggression and anxiety: social context and neurobiological links.

Authors:  Inga D Neumann; Alexa H Veenema; Daniela I Beiderbeck
Journal:  Front Behav Neurosci       Date:  2010-03-30       Impact factor: 3.558

Review 10.  Neurogenetics of dopaminergic receptor supersensitivity in activation of brain reward circuitry and relapse: proposing "deprivation-amplification relapse therapy" (DART).

Authors:  Kenneth Blum; Thomas J H Chen; B William Downs; Abdalla Bowirrat; Roger L Waite; Eric R Braverman; Margaret Madigan; Marlene Oscar-Berman; Nicholas DiNubile; Eric Stice; John Giordano; Siobhan Morse; Mark Gold
Journal:  Postgrad Med       Date:  2009-11       Impact factor: 3.840

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.